209 related articles for article (PubMed ID: 26431029)
1. Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.
Song X; Zhang C; Zhao M; Chen H; Liu X; Chen J; Lonard DM; Qin L; Xu J; Wang X; Li F; O'Malley BW; Wang J
PLoS One; 2015; 10(10):e0140011. PubMed ID: 26431029
[TBL] [Abstract][Full Text] [Related]
2. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.
Wang Y; Lonard DM; Yu Y; Chow DC; Palzkill TG; Wang J; Qi R; Matzuk AJ; Song X; Madoux F; Hodder P; Chase P; Griffin PR; Zhou S; Liao L; Xu J; O'Malley BW
Cancer Res; 2014 Mar; 74(5):1506-1517. PubMed ID: 24390736
[TBL] [Abstract][Full Text] [Related]
3. miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells.
Wang Q; Li C; Zhu Z; Teng Y; Che X; Wang Y; Ma Y; Wang Y; Zheng H; Liu Y; Qu X
Anticancer Drugs; 2016 Jan; 27(1):9-16. PubMed ID: 26398931
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
[TBL] [Abstract][Full Text] [Related]
5. Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.
Saenz FR; Ory V; Schmidt MO; Kallakury BV; Mueller SC; Furth PA; Wellstein A; Riegel AT
Neoplasia; 2019 Oct; 21(10):963-973. PubMed ID: 31437536
[TBL] [Abstract][Full Text] [Related]
6. Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway.
Liu XD; Song CY; Kong CC; Tian X
Chin J Integr Med; 2022 Oct; 28(10):900-908. PubMed ID: 34826043
[TBL] [Abstract][Full Text] [Related]
7. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
9. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
10. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
13. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
15. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
16. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
17. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
18. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
19. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
